Akcea Reports Financial Results and Highlights for Second Quarter 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ionis Pharmaceuticals (IONS) PT Raised to $50 at Stifel; Reiterates Hold
August 9, 2017 7:08 AM EDTStifel raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $50.00 (from $42.00) while maintaining a Hold rating following the company's 2Q. IONS reported a net loss of $(0.09)/share, narrowly missing Consensus estimates for $(0.11). Higher-than-estimated revenues of $105M drove most of the beat,... More
